{"product_id":"myriad-five-forces-analysis","title":"Myriad Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMyriad faces nuanced competitive pressures—from concentrated supplier leverage to evolving substitute technologies—that shape its margins and strategic options; this snapshot highlights key tensions and likely market shifts.\u003c\/p\u003e\n\u003cp\u003eThis brief only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore force-by-force ratings, visuals, and actionable recommendations to guide investment and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of sequencing technology providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary suppliers for Myriad Genetics are a few dominant sequencing-instrument and reagent makers—notably Illumina, which held roughly 70% of the short-read NGS market in 2024—giving suppliers high bargaining power and limiting Myriad’s ability to cut core-infrastructure costs.\u003c\/p\u003e\n\u003cp\u003eBecause of this concentration, supplier price hikes or 2024–2025 supply-chain shocks (chip shortages, reagent backlogs) can raise Myriad’s cost of goods sold and squeeze operating margins, as capital spend on sequencers often exceeds $1M per high-throughput unit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on specialized bioinformatics and cloud services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, genomic datasets are projected to exceed 2 exabytes globally, pushing Myriad to depend on high-end cloud and AI vendors for storage and analysis; these platforms are tightly embedded in Myriad’s diagnostics, so suppliers wield strong leverage. Migrating petabyte-scale archives and re-validating ML models can cost tens of millions and take 6–18 months, making switching costs prohibitive and strengthening supplier bargaining power during renewals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of highly skilled geneticists and lab technicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe supply of board-certified genetic counselors and molecular biologists remains tight: the US had ~6,300 genetic counselors in 2024 versus a projected need of +15% by 2030, and demand from precision medicine grew ~12% year-over-year in 2023–24. This scarcity gives specialized staff strong bargaining power, pushing Myriad’s labor costs up—labor is ~18–25% of diagnostics firms’ operating expenses, and Myriad reported rising SG\u0026amp;A per test in 2024. To keep its lead in test interpretation and clinical support, Myriad must boost recruitment and retention spending, likely raising total compensation and training budgets significantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatented reagents and proprietary chemicals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatented reagents and proprietary chemicals give suppliers high bargaining power over Myriad because many critical high‑purity components are single‑source and patent‑protected, forcing Myriad to accept set prices to keep assays validated and FDA\/CLIA compliant.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Myriad spent an estimated $45–55 million on outsourced specialty reagents (company filings), and supplier price hikes of 5–12% directly raise test COGS and margin pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle‑source patents raise switching costs\u003c\/li\u003e\n\u003cli\u003eRegulatory validation ties Myriad to specific reagents\u003c\/li\u003e\n\u003cli\u003eSupplier price increases pass to COGS, cutting margins\u003c\/li\u003e\n\u003cli\u003e2024 reagent spend ≈ $45–55M; price risk 5–12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and specialized cold-chain transport\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe transport of sensitive biological samples needs specialized cold-chain logistics that hold 2–8°C or -80°C reliably and meet same-day or next-flight delivery; failures in transit can void tests and cost Myriad millions—each major delay can lose $200–500 per sample in revenue and remediation (industry estimates 2024).\u003c\/p\u003e\n\u003cp\u003eOnly a few global firms (DHL Life Sciences, FedEx Clinical Solutions, UPS Healthcare) have the scale and validated processes to serve Myriad; their limited competition gives them bargaining power, shown by premium pricing: 15–40% markups on standard freight for certified cold-chain services in 2024.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eSpecialized temp ranges: 2–8°C, -20°C, -80°C\u003c\/li\u003e\n\u003cli\u003eSame-day\/overnight needed for many assays\u003c\/li\u003e\n\u003cli\u003eTop providers: DHL, FedEx, UPS\u003c\/li\u003e\n\u003cli\u003e2024 premium: 15–40% over normal freight\u003c\/li\u003e\n\u003cli\u003eTransit failures can cost $200–500\/sample\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Dominance Crushes Margins: Illumina ~70%, High Reagent \u0026amp; Cold‑Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers wield high bargaining power: Illumina ~70% short-read share (2024), reagent spend $45–55M (2024), price risk 5–12%, cold‑chain premiums 15–40%, labor tightness (6,300 US genetic counselors in 2024; +15% need by 2030), migration of petabytes costs tens of millions and 6–18 months—switching and regulatory validation keep costs and margins pressured.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIllumina market share\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent spend\u003c\/td\u003e\n\u003ctd\u003e$45–55M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice risk\u003c\/td\u003e\n\u003ctd\u003e5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain premium\u003c\/td\u003e\n\u003ctd\u003e15–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetic counselors (US)\u003c\/td\u003e\n\u003ctd\u003e~6,300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUncovers key drivers of competition, customer influence, and market entry risks tailored exclusively for Myriad, evaluating supplier\/buyer power, substitutes, and emerging disruptors with strategic commentary for investor and internal use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise one-sheet Porter's Five Forces summary that highlights competitive pressures and strategic levers—ideal for swift boardroom decisions or investor memos.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of third-party payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge private insurers and government payers like medicare control pricing coverage for genetic tests with the top us covering of lives as giving them outsized leverage over myriad.\u003e\n\u003cpthey set reimbursement rates and clinical utility rules medicare local coverage determinations national policies can cut by instantly shrinking myriad addressable market.\u003e\n\u003cpif a major insurer drops coverage for specific test myriad can lose tens of millions in annual revenue quickly reimbursements alone drove\u003e$100M of legacy revenues in prior years—so payer concentration is a strategic risk.\n\u003c\/pif\u003e\u003c\/pthey\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of large health systems and oncology networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsolidation has produced hospital systems controlling ~40% of US hospital beds (American Hospital Association, 2024), letting them negotiate bulk diagnostic contracts that push prices down 10–25% per test. Large oncology networks deliver high sample volumes—sometimes \u0026gt;100,000 tests\/year—to demand discounted rates and bundled data services. Myriad competes for preferred-lab status, often accepting lower per-test margins to secure volume and integrated data-access deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising consumer price sensitivity in direct markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith high-deductible health plans covering 45% of US workers by 2024, patients now pay more diagnostic costs out‑of‑pocket, raising price sensitivity and shopping for cheaper tests.\u003c\/p\u003e\n\u003cp\u003eMyriad faces higher churn risk as consumers compare prices; a 2023 survey found 38% delayed or skipped diagnostics for cost reasons, pressuring Myriad to show transparent pricing.\u003c\/p\u003e\n\u003cp\u003eOffering clear price lists and expanding financial assistance (like income‑based discounts) is critical to retain volume against lower‑cost competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician autonomy and brand preference\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePhysicians, not insurers, usually pick genetic tests, so Myriad’s clinical sales teams invest heavily to build loyalty and show superior clinical utility—Myriad reported $1.1B revenue in 2024, with major spend on field sales and medical affairs to sustain prescribing habits.\u003c\/p\u003e\n\u003cp\u003eStill, large health systems and payers are adopting standardized clinical pathways and preferred-vendor contracts, which reduce individual physician choice and pressure Myriad on price and access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysician-led ordering: primary influence on test selection\u003c\/li\u003e\n\u003cli\u003eMyriad investment: large clinical sales \u0026amp; educational programs\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $1.1B signals scale of physician engagement\u003c\/li\u003e\n\u003cli\u003eThreat: health-system pathways and payer formularies limit autonomy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-based requirements from regulatory bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpgovernment health authorities and regulatory agencies act as indirect customers by defining which genetic tests are valid necessary their requirements determine reimbursement clinical adoption.\u003e\u003cptheir power comes from demanding large clinical trials and long-term outcome studies for example fda cms often expect multi-year health-economics data reported million r in to meet such demands.\u003e\u003cpmyriad must keep investing in r and registries to retain market access failing this can delay approvals cut revenue streams tied payer coverage.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulators set clinical standards and reimbursement rules\u003c\/li\u003e\n\u003cli\u003eRequire multi-year trials and real-world outcomes\u003c\/li\u003e\n\u003cli\u003eMyriad spent $120M on R\u0026amp;D in 2024\u003c\/li\u003e\n\u003cli\u003eNoncompliance risks approval delays and lost revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmyriad\u003e\u003c\/ptheir\u003e\u003c\/pgovernment\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurers’ squeeze: Top payers and hospitals threaten Myriad pricing, risking big revenue hits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cplarge private insurers and medicare control pricing us cover of lives payers strong leverage over myriad reimbursement access.\u003e\u003cpmajor insurers and hospital systems demand price cuts bundled deals losing coverage can cut tens of millions\u003e$100M historically).\u003cppatients cost-sharing on hdhps raises price sensitivity physicians still choose tests but system pathways reduce that autonomy.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑5 insurer coverage\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital system bed share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyriad revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHDHP workers\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/ppatients\u003e\u003c\/pmajor\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eMyriad Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Myriad Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders, no samples.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the full, professionally formatted file you can download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final deliverable: the same analysis, ready for immediate application with clear insights on competitive rivalry, supplier and buyer power, threats of entry and substitutes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747304452473,"sku":"myriad-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/myriad-five-forces-analysis.png?v=1772197388","url":"https:\/\/matrixbcg.com\/products\/myriad-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}